Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America

Helen W. Boucher, George H. Talbot, John S. Bradley, John E. Edwards, David Gilbert, Louis B. Rice, Michael Scheld, Brad Spellberg, John Bartlett

Research output: Contribution to journalArticle

Abstract

The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure - one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalClinical Infectious Diseases
Volume48
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Pharmaceutical Preparations
United States Food and Drug Administration
Communicable Diseases
United States Dept. of Health and Human Services
National Institutes of Health (U.S.)
Centers for Disease Control and Prevention (U.S.)
Infection
Parity
Research
Biomedical Research
Industry
Public Health
Anti-Bacterial Agents
Therapeutics

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., ... Bartlett, J. (2009). Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases, 48(1), 1-12. https://doi.org/10.1086/595011

Bad bugs, no drugs : No ESKAPE! An update from the Infectious Diseases Society of America. / Boucher, Helen W.; Talbot, George H.; Bradley, John S.; Edwards, John E.; Gilbert, David; Rice, Louis B.; Scheld, Michael; Spellberg, Brad; Bartlett, John.

In: Clinical Infectious Diseases, Vol. 48, No. 1, 01.01.2009, p. 1-12.

Research output: Contribution to journalArticle

Boucher, HW, Talbot, GH, Bradley, JS, Edwards, JE, Gilbert, D, Rice, LB, Scheld, M, Spellberg, B & Bartlett, J 2009, 'Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America', Clinical Infectious Diseases, vol. 48, no. 1, pp. 1-12. https://doi.org/10.1086/595011
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009 Jan 1;48(1):1-12. https://doi.org/10.1086/595011
Boucher, Helen W. ; Talbot, George H. ; Bradley, John S. ; Edwards, John E. ; Gilbert, David ; Rice, Louis B. ; Scheld, Michael ; Spellberg, Brad ; Bartlett, John. / Bad bugs, no drugs : No ESKAPE! An update from the Infectious Diseases Society of America. In: Clinical Infectious Diseases. 2009 ; Vol. 48, No. 1. pp. 1-12.
@article{50ee20244c61451fb202618495e91385,
title = "Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America",
abstract = "The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, {"}Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews,{"} and recently issued a {"}Call to Action{"} to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure - one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.",
author = "Boucher, {Helen W.} and Talbot, {George H.} and Bradley, {John S.} and Edwards, {John E.} and David Gilbert and Rice, {Louis B.} and Michael Scheld and Brad Spellberg and John Bartlett",
year = "2009",
month = "1",
day = "1",
doi = "10.1086/595011",
language = "English (US)",
volume = "48",
pages = "1--12",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Bad bugs, no drugs

T2 - No ESKAPE! An update from the Infectious Diseases Society of America

AU - Boucher, Helen W.

AU - Talbot, George H.

AU - Bradley, John S.

AU - Edwards, John E.

AU - Gilbert, David

AU - Rice, Louis B.

AU - Scheld, Michael

AU - Spellberg, Brad

AU - Bartlett, John

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure - one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.

AB - The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure - one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.

UR - http://www.scopus.com/inward/record.url?scp=57749107808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749107808&partnerID=8YFLogxK

U2 - 10.1086/595011

DO - 10.1086/595011

M3 - Article

C2 - 19035777

AN - SCOPUS:57749107808

VL - 48

SP - 1

EP - 12

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 1

ER -